Associated tags: Analysis, Fortune 500, Table, Pharmaceutical industry, Research, USD
Locations: LONDON, ASIA, PH, UNITED STATES OF AMERICA, UNITED KINGDOM, MIDDLE EAST, HUNGARY, EUROPE, LATIN AMERICA, NORTH AMERICA, CHINA, GERMANY, UK, CANADA, US, JAPAN, ENGLAND, FRANCE, TURKEY, BRAZIL, SPAIN, ITALY, INDIA, IRAN, ARGENTINA, MEXICO
Retrieved on:
Tuesday, January 16, 2024
Biotron,
Regenerative medicine,
Research,
Toxicology,
Incidence,
B cell,
Extracellular matrix,
Immortalised cell line,
ECM,
Tissue,
Drug discovery,
Zeiss,
Tissue engineering,
3D,
Drug development,
FDA,
Microcarrier,
Growth,
3D printing LONDON, Jan. 16, 2024 /PRNewswire/ --
Key Points:
- Also, the maintenance of 3D cell culture equipment is complex and requires specialized training or skilled personnel, which enhances the overall cost of installing 3D cell culture.
- Despite the market restraints, the 3D cell culture market is growing exponentially due to the increasing trend of personalized medicine and ongoing technological advancements to enhance the reproducibility of 3D cell culture-based experiments.
- Based on the scaffold format, the 3D cell culture market is dominated by scaffold-based format, capturing 46% of the market share by 2035.
- Based on the key geographical region, North America will dominate the 3D cell culture market, capturing 39% of the overall market share by 2035.
Retrieved on:
Tuesday, January 16, 2024
Cloud,
Fifth Third Bank,
Health information management,
Big data,
Privacy,
Hospital,
Research,
Overalls,
DARPA,
Data management,
Electronic health record,
Immortalised cell line,
Clinic,
Software,
Drug development,
Mental Hygiene,
Financial management,
Growth,
Retail LONDON, Jan. 16, 2024 /PRNewswire/ --
Key Points:
- Big data in the healthcare market is expanding gradually across the globe owing to its wide-scale adoption for data management and analysis ability.
- Based on the application areas, the big data in healthcare market is dominated by clinical data management, capturing 28% of the overall revenue share by 2035.
- Based on the healthcare vertical, the big data in healthcare market is segmented into healthcare services, medical devices, pharmaceuticals, and other verticals.
- Based on the healthcare vertical, the big data in healthcare market is dominated by pharmaceuticals, capturing 36% by 2035.
Retrieved on:
Tuesday, January 16, 2024
Cloud,
Fifth Third Bank,
Health information management,
Big data,
Privacy,
Hospital,
Research,
Overalls,
DARPA,
Data management,
Electronic health record,
Immortalised cell line,
Clinic,
Software,
Drug development,
Mental Hygiene,
Financial management,
Growth,
Retail LONDON, Jan. 16, 2024 /PRNewswire/ --
Key Points:
- Big data in the healthcare market is expanding gradually across the globe owing to its wide-scale adoption for data management and analysis ability.
- Based on the application areas, the big data in healthcare market is dominated by clinical data management, capturing 28% of the overall revenue share by 2035.
- Based on the healthcare vertical, the big data in healthcare market is segmented into healthcare services, medical devices, pharmaceuticals, and other verticals.
- Based on the healthcare vertical, the big data in healthcare market is dominated by pharmaceuticals, capturing 36% by 2035.
Research,
UPLC,
Biotechnology,
Thermo Fisher Scientific,
QC,
Chromatography,
Acquisition,
Laboratory,
Automation,
Valmet,
Particle size,
Growth,
Instrumentation LONDON, Jan. 15, 2024 /PRNewswire/ -- The global chromatography instrumentation market is growing rapidly; it is estimated to be worth USD 7.6 billion in 2023 and is anticipated to reach USD 14 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 5.3% during the forecast period from 2023 to 2035.
Key Points:
- Secondly, the chromatography instrumentation market is also driven by the rapidly evolving purification process-specific requirements across different industries.
- The high cost associated with the development of chromatography instrumentation and operational expenditures are the two major market restraints that impede the growth of the market.
- The lack of skilled personnel to operate the instrument is considered a key market restraint that restricts the growth of the chromatography instrumentation market.
- Request Free Sample PDF Copy at:
Based on the type of chromatography instruments, the market is segmented into liquid chromatography, gas chromatography, and other systems.
Research,
UPLC,
Biotechnology,
Thermo Fisher Scientific,
QC,
Chromatography,
Acquisition,
Laboratory,
Automation,
Valmet,
Particle size,
Growth,
Instrumentation LONDON, Jan. 15, 2024 /PRNewswire/ -- The global chromatography instrumentation market is growing rapidly; it is estimated to be worth USD 7.6 billion in 2023 and is anticipated to reach USD 14 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 5.3% during the forecast period from 2023 to 2035.
Key Points:
- Secondly, the chromatography instrumentation market is also driven by the rapidly evolving purification process-specific requirements across different industries.
- The high cost associated with the development of chromatography instrumentation and operational expenditures are the two major market restraints that impede the growth of the market.
- The lack of skilled personnel to operate the instrument is considered a key market restraint that restricts the growth of the chromatography instrumentation market.
- Request Free Sample PDF Copy at:
Based on the type of chromatography instruments, the market is segmented into liquid chromatography, gas chromatography, and other systems.
Warburg Pincus,
HUF,
Blister,
Overalls,
Route of administration,
API,
OneSource,
Advent International,
Investment,
Acquisition,
Drug development,
Stelis,
FDF,
Baxter International,
Organization,
CDMO,
CMOS,
Egis,
Clinical trial,
Growth,
Fine chemical LONDON, Jan. 15, 2024 /PRNewswire/ -- The global pharmaceutical contract manufacturing market is anticipated to be worth USD 90 billion in 2023 and is expected to reach USD 140 billion by 2030. It is estimated to grow at a compounded annual growth rate of 6.5% during the forecast period (2022-2030).
Key Points:
- The global pharmaceutical contract manufacturing market faces challenges in the form of high initial investment costs for equipment and facilities.
- Commercial segment will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 81% by 2030.
- Based on the type of end users, the pharmaceutical contract manufacturing market is segmented into small, mid-sized, and large pharmaceutical companies.
- Asia-Pacific will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 37% of the market share by 2030.
Blister,
Overalls,
Route of administration,
API,
OneSource,
Advent International,
Investment,
Acquisition,
Medication,
Drug development,
Stelis,
FDF,
Baxter International,
Organization,
CDMO,
CMOS,
Clinical trial,
Growth,
Fine chemical LONDON, Jan. 15, 2024 /PRNewswire/ -- The global pharmaceutical contract manufacturing market is anticipated to be worth USD 90 billion in 2023 and is expected to reach USD 140 billion by 2030. It is estimated to grow at a compounded annual growth rate of 6.5% during the forecast period (2022-2030).
Key Points:
- The global pharmaceutical contract manufacturing market faces challenges in the form of high initial investment costs for equipment and facilities.
- Commercial segment will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 81% by 2030.
- Based on the type of end users, the pharmaceutical contract manufacturing market is segmented into small, mid-sized, and large pharmaceutical companies.
- Asia-Pacific will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 37% of the market share by 2030.
Retrieved on:
Thursday, January 11, 2024
Artificial intelligence,
Swelling,
Dermatology,
Research,
Hospital,
Bruise,
Face,
Partnership,
MENA,
Risk,
Skin,
Filler (linguistics),
Allergan,
Muscle weakness,
Virtual reality,
Ageing,
Growth,
Beauty salon LONDON, Jan. 11, 2024 /PRNewswire/ -- The global dermal fillers market is estimated to be worth USD 3.1 billion in 2023 and is anticipated to reach USD 8.8 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 9.18% during the forecast period from 2023 to 2035.
Key Points:
- Though the dermal fillers market is expanding positively across the globe, several restraints may impact the growth.
- The dermal fillers market is witnessing several collaborations between key players to enhance the development of advanced dermal filler formulations.
- Based on gender, the dermal fillers market is led by females, capturing 90% of the market share in 2023.
- The dermal fillers market report also includes detailed profiles of key players (listed below) that provide innovative vial solutions.
Retrieved on:
Thursday, January 11, 2024
Artificial intelligence,
Swelling,
Dermatology,
Research,
Hospital,
Bruise,
Face,
Partnership,
MENA,
Risk,
Skin,
Filler (linguistics),
Allergan,
Muscle weakness,
Virtual reality,
Ageing,
Growth,
Beauty salon LONDON, Jan. 11, 2024 /PRNewswire/ -- The global dermal fillers market is estimated to be worth USD 3.1 billion in 2023 and is anticipated to reach USD 8.8 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 9.18% during the forecast period from 2023 to 2035.
Key Points:
- Though the dermal fillers market is expanding positively across the globe, several restraints may impact the growth.
- The dermal fillers market is witnessing several collaborations between key players to enhance the development of advanced dermal filler formulations.
- Based on gender, the dermal fillers market is led by females, capturing 90% of the market share in 2023.
- The dermal fillers market report also includes detailed profiles of key players (listed below) that provide innovative vial solutions.
Retrieved on:
Wednesday, January 10, 2024
Neurological disorder,
Centre for Process Innovation,
University of Manchester,
Overalls,
Oligonucleotide,
Intrinsic termination,
DNA,
Nucleotide,
API,
DSM-IV codes,
MicroRNA,
University,
Novartis,
Small RNA,
Genetic testing,
COVID-19,
EUR,
Therapy,
FDF,
AstraZeneca,
Fine chemical LONDON, Jan. 10, 2024 /PRNewswire/ -- The global oligonucleotide synthesis market is anticipated to be worth USD 3.5 billion in 2023, and it is expected to reach 9.9 billion by 2035. It is estimated to grow at a compounded annual growth rate (CAGR) of 16.1% during the forecast period (2023-2035).
Key Points:
- The oligonucleotide synthesis market faces several challenges, including the complexity of synthesis procedures, purification difficulties, gaps in analytical expertise, cost intensiveness, and regulatory constraints.
- The growth factors for the oligonucleotide synthesis market include the expanding applications of oligonucleotides in genetic testing, diagnostics, and therapeutics.
- Recent Developments in Oligonucleotide Synthesis Market:
Several recent developments have taken place in the field of oligonucleotide synthesis.
- FDF operation will dominate the oligonucleotide synthesis market during the forecast period and is anticipated to capture 53% of the market share in 2023.
